依达拉奉治疗急性一氧化碳中毒疗效及安全性分析  

The efficacy and safety of Edaravone in the treatment of acute carbon monoxide poisoning

作　　者：张禹[1] 杨晨[1] 孟娟[1] 吕艳[1] 胡慧军[1] 潘树义[1] 

机构地区：[1]海军总医院高压氧科,北京100048

出　　处：《中国医药导报》2012年第13期79-80,共2页China Medical Herald

摘　　要：目的观察依达拉奉治疗急性一氧化碳中毒的疗效及其在预防迟发脑病方面的作用,并分析其临床安全性。方法将患者随机分为治疗组30例,对照组35例,对照组给予高压氧治疗及常规药物治疗,治疗组在对照组治疗的基础上加用依达拉奉注射液,30 mg/d,静脉滴注,连用7 d。观察比较两组的临床疗效、MMSE智力量表评分及迟发脑病发生率,并在依达拉奉治疗前后观察患者肝肾功能变化。结果治疗组总有效率为93.33%,高于对照组(P<0.05);治疗组MMSE评分高于对照组(P<0.05);两组迟发脑病发生率比较差异无统计学意义(P>0.05);治疗组依达拉奉治疗后谷丙转氨酶较治疗前有升高(P<0.05)。结论依达拉奉治疗重度一氧化碳中毒疗效确切,安全性方面依达拉奉可能会加重肝功能异常患者的肝损害,对肾功能无明显影响。Objective To evaluate the clinical effect and security of Edaravone in acute carbon monoxide poisoning and investigate its role in prevention of delayed encephalopathy after acute carbon monoxide poisoning.Methods Thirty cases of acute carbon monoxide poisoning were randomly divided into treatment group and control group.35 cases in treatment group were administrated with Edaravone（30 mg/d with intra vein infusions for 7 days） combined hypobaric oxygen therapy and internal comprehensive treatments,30 cases in control group were treated only by hypobaric oxygen therapy and internal comprehensive treatments.The clinical effective was evaluated by near-term outcome,mini-mental state examination（MMSE）,the incidence of delayed encephalopathy after acute carbon monoxide poisoning,liver and renal functions before and after the treatment.Results The total effective rate in treatment group was 93.33%,which was significantly superior to that in control group（P〈0.05）.MMSE score was also higher in treatment group than that in control group（P〈0.05）.However,the serum alanine aminotransferase（ALT） level was elevated after Edaravone treatment.Conclusion Our study suggests that Edaravone is an effective adjuvant therapy in patients with acute carbon monoxide poisoning.However,Edaravone is not recommended in the patients with liver function impairment,which may aggravate liver damage but has little effect on renal function.

关 键 词：依达拉奉 急性一氧化碳中毒 疗效 

分 类 号：R595.1[医药卫生—内科学]